Axsome Therapeutics, Inc. (AXSM) Insider Trading Activity

Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.

Show less

Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $200,466 and sold $152.48M worth of Axsome Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $272,797 and sold $64.19M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Coleman Mark (director) — $200,466.

The last purchase of 1,575 shares for transaction amount of $200,466 was made by Coleman Mark (director) on 2025‑09‑08.